<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876042</url>
  </required_header>
  <id_info>
    <org_study_id>360047-001</org_study_id>
    <nct_id>NCT02876042</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>HFpEF</acronym>
  <official_title>BAROSTIM THERAPY ™ in Heart Failure With Preserved Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry (NCT02876042) is to evaluate the effect of BAROSTIM THERAPY with&#xD;
      the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the&#xD;
      CE-Marked indication for resistant hypertension that also have evidence of heart failure with&#xD;
      preserved ejection fraction (HFpEF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary:&#xD;
&#xD;
      The CVRx BAROSTIM THERAPY in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry&#xD;
      will be performed with subjects who have been recently implanted with the BAROSTIM NEO System&#xD;
      in accordance with CE-Mark approved criteria for resistant hypertension and have evidence of&#xD;
      HFpEF per the registry enrollment criteria. Subjects must be enrolled within 30 days from&#xD;
      implant but prior to therapy activation. Up to 70 subjects will be enrolled at up to 10&#xD;
      sites. Data should be obtained from standard of care measurements taken prior to implant, at&#xD;
      enrollment/baseline, and at 3 and 6 months after the device was implanted, at which time each&#xD;
      subject will be exited from the registry.&#xD;
&#xD;
      Eligibility Criteria:&#xD;
&#xD;
      The CE-Mark approved indications and contraindications for the BAROSTIM NEO system in the&#xD;
      treatment of resistant hypertension include:&#xD;
&#xD;
        -  Indications&#xD;
&#xD;
             -  Systolic blood pressure greater than or equal to 140 mmHg, and&#xD;
&#xD;
             -  Resistance to maximally tolerated therapy with a diuretic and two other&#xD;
                anti-hypertension medications&#xD;
&#xD;
        -  Contraindications&#xD;
&#xD;
             -  Bilateral carotid bifurcations located above the level of the mandible&#xD;
&#xD;
             -  Baroreflex failure or autonomic neuropathy&#xD;
&#xD;
             -  Uncontrolled, symptomatic cardiac bradyarrhythmias&#xD;
&#xD;
             -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation&#xD;
                to be greater than 50%&#xD;
&#xD;
             -  Ulcerative plaques in the carotid artery as determined by ultrasound or&#xD;
                angiographic evaluation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2017</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Changes in Office Cuff Systolic Blood Pressure</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>Office cuff blood pressure measurement to be obtained from a time point prior to implant and as close to the implant procedure as possible (baseline), and at 3 and 6 months post-implant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in New York Heart Association Functional Classification</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>New York Heart Association Classification, if available, should be obtained from a time point prior to implant and as close to the implant procedure as possible (baseline), and at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Left Ventricular Mass Index</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>An echocardiogram obtained prior to implant, and as close to the implant procedure as possible, will be utilized for the baseline measurement. An additional echocardiogram will be obtained at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in LA volume index</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>An echocardiogram obtained prior to implant, and as close to the implant procedure as possible, will be utilized for the baseline measurement. An additional echocardiogram will be obtained at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in E/E' ratio</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>An echocardiogram obtained prior to implant, and as close to the implant procedure as possible, will be utilized for the baseline measurement. An additional echocardiogram will be obtained at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in NT-proBNP</measure>
    <time_frame>Pre-implant baseline, 6 months post-implant</time_frame>
    <description>If available, measurement should be obtained from a time point prior to implant and as close to the implant procedure as possible (baseline), and at 3 and 6 months post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate health care utilization over follow-up, such as heart failure hospitalizations</measure>
    <time_frame>Pre-implant baseline to 6 months post-implant</time_frame>
    <description>Health care utilization information is collected throughout follow-up.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BAROSTIM NEO™ System</intervention_name>
    <description>Implantation of the BAROSTIM NEO™ System</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The CVRx BAROSTIM THERAPY in Heart Failure with Preserved Ejection Fraction (HFpEF)&#xD;
        Registry will be performed with subjects who have been recently implanted with the BAROSTIM&#xD;
        NEO System in accordance with CE-Mark approved criteria for resistant hypertension and have&#xD;
        evidence of HFpEF per the registry enrollment criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign an Ethics Committee (EC) approved informed consent form for the registry.&#xD;
&#xD;
          -  Implanted with the BAROSTIM NEO system in accordance with CE-Mark approved indications&#xD;
             and contraindications for resistant hypertension within 30 days prior to enrollment.&#xD;
&#xD;
          -  BAROSTIM THERAPY not yet chronically activated.&#xD;
&#xD;
          -  Pre-implant echocardiogram with left ventricular ejection fraction ≥ 50% within 30&#xD;
             days prior to implant.&#xD;
&#xD;
          -  On stable, maximally-tolerated, guideline-directed cardiovascular medications for at&#xD;
             least 30 days prior to enrollment.&#xD;
&#xD;
          -  Objective evidence of heart failure according to the following criteria:&#xD;
&#xD;
               -  Hospitalization for heart failure within 12 months prior to enrollment OR&#xD;
&#xD;
               -  Echocardiographic evidence of diastolic dysfunction (LA Volume Index &gt;34 ml/m2 OR&#xD;
                  E/e &gt;13) within 30 days prior to enrollment OR&#xD;
&#xD;
               -  NTproBNP &gt; 220 pg/mL or BNP &gt; 80 pg/mL (in atrial fibrillation, NTproBNP &gt; 600&#xD;
                  pg/mL or BNP &gt; 200 pg/mL) within 30 days prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure secondary to a reversible or treatable condition such as, cardiac&#xD;
             structural valvular disease, acute myocarditis and pericardial constriction.&#xD;
&#xD;
          -  Heart failure secondary to right ventricular failure or right ventricular myocardial&#xD;
             infarction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burkert Pieske, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätmedizin Berlin - Charité</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Galle</last_name>
    <phone>763-416-2876</phone>
    <email>lgalle@cvrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Berlin Charité &amp; Deutschen Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Immanuel Klinikum Bernau Herzzentrum Brandenburg</name>
      <address>
        <city>Bernau</city>
        <zip>16321</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lippe Klinikum</name>
      <address>
        <city>Detmold</city>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen und Marburg</name>
      <address>
        <city>Gießen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Hellwig</last_name>
      <phone>+49 641 985 42632</phone>
      <email>gabriele.hellwig@med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Jörn Schmitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Neumann</last_name>
      <phone>+49 401818818635</phone>
      <email>chris.neumann@asklepios.com</email>
    </contact>
    <investigator>
      <last_name>Jochen Müller-Ehmsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonie Grossekettler</last_name>
      <phone>+49 6221 563 7758</phone>
      <email>leonie.grossekettler@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Philip Raake</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kardiologie im Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln Herzzentrum</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatjana Schewior</last_name>
      <phone>+49 22147888273</phone>
      <email>tatjana.schewior@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Marcel Halbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marienkrankenhaus Siegen</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.barostimtherapy.com/</url>
    <description>BAROSTIM THERAPY website</description>
  </link>
  <reference>
    <citation>Georgakopoulos D, Little WC, Abraham WT, Weaver FA, Zile MR. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction. J Card Fail. 2011 Feb;17(2):167-78. doi: 10.1016/j.cardfail.2010.09.004. Epub 2010 Oct 29. Review.</citation>
    <PMID>21300307</PMID>
  </reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 15, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

